Sumitomo Chemical
Search results
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management.
- Open400.00High426.00Low400.00
- Mkt Cap163.68BP/E (TTM)N/ADiv & Yield14.00 & 3.47%
- Prev. Close408.0052 Wk. Low279.0052 Wk. High670.60
Related stocks
We drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Learn More.
SMPA is committed to accelerating scientific and therapeutic breakthroughs on behalf of patients in critical disease areas across psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies.
Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas.
About Us. For the betterment of healthcare and fuller lives of people worldwide, we will continue to contribute to the society as a whole, by creating new values based on research and development.
Sumitomo Pharma is a research and development-oriented pharmaceutical company that continuously takes on challenges to develop innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.
Jul 10, 2023 · CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ — Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in the U.S. and related markets.
